Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
Just caught STIM popping off in premarket - up nearly 30% to $1.89 after Neuronetics dropped their Q4 numbers. Pretty solid performance actually. Q4 revenue hit $41.8M, that's 86% growth year-over-year from $22.49M. Full year came in at $149.2M, basically doubled from $74.9M the year before.
The real driver seems to be their NeuroStar system gaining traction. They shipped 49 units in Q4 alone, and the device revenue specifically jumped to $18.3M from just $3.8M a year ago. For context, NeuroStar is this non-invasive therapy system they use for treating major depressive disorder and OCD. Clinic revenue from the device also spiked to $23.5M versus $4.4M in the same quarter last year.
What caught my attention is they're actually generating positive operating cash flow now and sitting on $34.1M in cash. The CEO mentioned they're translating this revenue growth into actual profitability, which is always a good sign. They're planning to release full Q4 results on March 17, so there might be more detail coming. Definitely one to watch if you're looking at healthcare tech plays with real revenue momentum.